Morphosys and Novartis select second area for antibody co-development
This article was originally published in Scrip
Executive Summary
Morphosys and Novartis have identified a second area in which the two companies will co-develop therapeutic antibodies as part of their $600 million 10-year deal, signed in 2007. It has never been clear exactly what the commercial expectations of that agreement were. However, Morphosys's CEO Dr Simon Moroney told Scrip that although the selection of programmes by Novartis had been "slightly more spread-out" than he would have hoped for, there had been no fixed timeline for selecting programmes for co-development.